Is Tenable Stock a Buy, Sell or Hold?
Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…
Sell
37
ZYME Quote, Financials, Valuation and Earnings
Last price:
$12.72
Seasonality move
:
11.75%
Day range:
$12.64 - $13.03
52-week range:
$7.97 - $17.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.65x
P/B ratio:
2.61x
Volume:
800.2K
Avg. volume:
623.6K
1-year change:
19.44%
Market cap:
$885M
Revenue:
$76.3M
EPS (TTM):
-$1.61
Analysts' Opinion
-
Consensus RatingZymeworks has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.35, Zymeworks has an estimated upside of 67.85% from its current price of $12.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $12.72.
Fair Value
-
According to the consensus of 9 analysts, Zymeworks has 67.85% upside to fair value with a price target of $21.35 per share.
ZYME vs. S&P 500
-
Over the past 5 trading days, Zymeworks has overperformed the S&P 500 by 3.31% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Zymeworks does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zymeworks has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Zymeworks reported revenues of $31M.
Earnings Growth
-
Zymeworks has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Zymeworks reported earnings per share of -$0.31.
Enterprise value:
659.2M
EV / Invested capital:
1.95x
Price / LTM sales:
12.65x
EV / EBIT:
--
EV / Revenue:
8.64x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.83x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-23.59%
Net Income Margin (TTM):
-160.8%
Return On Equity:
-30.45%
Return On Invested Capital:
-30.45%
Operating Margin:
-71.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $412.5M | $76M | $76.3M | $16.9M | $31M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | $130.5M | -$138.1M | -$119.9M | -$23.4M | -$22.2M | |
| EBITDA | $142.5M | -$120.8M | -$108.7M | -$20.1M | -$18.5M | |
| Diluted EPS | $1.77 | -$1.73 | -$1.61 | -$0.19 | -$0.31 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $455.1M | $288.2M | $544.7M | $412.9M | $300.5M | |
| Total Assets | $538.4M | $389.1M | $648.7M | $580.9M | $463.1M | |
| Current Liabilities | $85.7M | $71.9M | $95.6M | $55.8M | $88.3M | |
| Total Liabilities | $128.5M | $140M | $155.8M | $116.1M | $124.3M | |
| Total Equity | $409.9M | $249.1M | $493M | $464.8M | $338.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $144.1M | -$118.3M | -$110M | $14M | -$41.5M | |
| Cash From Investing | -$53.8M | -$207.3M | $38.8M | -$1.3M | -$6.2M | |
| Cash From Financing | $108.6M | $81.8M | -$20.5M | $50.6M | -$8.6M | |
| Free Cash Flow | $131M | -$122.4M | -$113.1M | $12.2M | -$41.8M | |
ZYME
Sector
Market Cap
$885M
$39.2M
Price % of 52-Week High
71.86%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
19.44%
-38.63%
Beta (5-Year)
1.134
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$12.56
200-day SMA
Buy
Level
$12.40
Bollinger Bands (100)
Sell
Level
12.96 - 15.16
Chaikin Money Flow
Sell
Level
-22.1M
20-day SMA
Sell
Level
$12.88
Relative Strength Index (RSI14)
Sell
Level
47.14
ADX Line
Sell
Level
24.07
Williams %R
Neutral
Level
-20.7207
50-day SMA
Sell
Level
$13.77
MACD (12, 26)
Sell
Level
-0.38
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
92.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.2231)
Buy
CA Score
(Annual)
Level (-0.2048)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.0416)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Stock Forecast FAQ
In the current month, ZYME has received 7 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ZYME average analyst price target in the past 3 months is $21.35.
-
Where Will Zymeworks Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zymeworks share price will rise to $21.35 per share over the next 12 months.
-
What Do Analysts Say About Zymeworks?
Analysts are divided on their view about Zymeworks share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zymeworks is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Zymeworks's Price Target?
The price target for Zymeworks over the next 1-year time period is forecast to be $21.35 according to 9 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ZYME A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zymeworks is a Buy. 7 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ZYME?
You can purchase shares of Zymeworks via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zymeworks shares.
-
What Is The Zymeworks Share Price Today?
Zymeworks was last trading at $12.72 per share. This represents the most recent stock quote for Zymeworks. Yesterday, Zymeworks closed at $12.72 per share.
-
How To Buy Zymeworks Stock Online?
In order to purchase Zymeworks stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is CyberArk Stock a Buy, Sell or Hold?
CyberArk Software (NASDAQ:CYBR), the identity security and management firm, has…
Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
